Combination of local and systemic immunomodulative therapies for melanoma and liver cancer
US9808524B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 24, 2015 |
| Grant date | Nov 7, 2017 |
| Priority date | — |
| Expiry date | Jun 24, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/16034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.